Both FXR and PPARα/δ agonists have been studied in late-stage clinical trials to treat NASH, and while attractive therapeutic effects were observed for OCA and elafibranor, the individual efficacy of these compounds appears insufficient to reverse NASH. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatohepatitis.